Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.26M | 68.70M | 48.73M | 25.10M | 115.53M | 24.29M |
Gross Profit | 565.00K | 68.70M | 40.47M | 16.09M | 115.53M | 24.29M |
EBITDA | -73.73M | 13.53M | -32.04M | -62.79M | -20.27M | -99.19M |
Net Income | -78.25M | 7.17M | -61.32M | -122.91M | -30.92M | -109.01M |
Balance Sheet | ||||||
Total Assets | 108.93M | 136.39M | 159.78M | 238.17M | 211.50M | 150.16M |
Cash, Cash Equivalents and Short-Term Investments | 62.24M | 86.31M | 116.68M | 189.58M | 143.66M | 89.80M |
Total Debt | 29.45M | 30.05M | 31.27M | 27.04M | 9.11M | 10.52M |
Total Liabilities | 74.87M | 80.00M | 140.92M | 177.74M | 120.33M | 105.73M |
Stockholders Equity | 34.05M | 56.39M | 18.86M | 60.43M | 91.17M | 44.42M |
Cash Flow | ||||||
Free Cash Flow | -64.12M | -58.70M | -86.39M | -49.07M | -16.66M | -92.42M |
Operating Cash Flow | -63.92M | -58.45M | -84.11M | -45.75M | -10.85M | -87.39M |
Investing Cash Flow | -487.00K | -215.00K | 5.83M | -3.32M | -5.80M | -5.03M |
Financing Cash Flow | 25.64M | 50.45M | 5.39M | 94.98M | 70.52M | 1.33M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $343.02M | 3.71 | 108.21% | ― | 18.01% | 306.76% | |
51 Neutral | $7.91B | -0.36 | -41.70% | 2.23% | 23.45% | -1.86% | |
51 Neutral | $58.93M | 2.40 | -143.89% | ― | -98.56% | -347.81% | |
51 Neutral | ― | ― | 127.51% | 56.94% | |||
41 Neutral | $149.39M | ― | -23.76% | ― | -100.00% | 55.32% | |
36 Underperform | $40.89M | ― | -47.87% | ― | ― | 18.86% | |
27 Underperform | $61.14M | ― | -64.39% | ― | ― | 48.45% |
On August 26, 2025, Precision BioSciences amended and restated employment agreements for its key executives to retain them and reflect updated compensation terms. These agreements include provisions for termination without cause and require funding of severance and expenses in an escrow account, with interest and unused funds benefiting the company.
On August 6, 2025, Precision BioSciences announced results from its Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, a treatment for hepatitis B. The trial’s Cohort 1, which involved three patients receiving low-dose PBGENE-HBV, showed promising safety and efficacy results, with no serious adverse events and significant reductions in hepatitis B surface antigen levels. Cohort 2 is underway, with one patient completing three doses and two others receiving one dose each, showing similar safety profiles. The favorable outcomes have led to the recommendation to initiate Cohort 3, with further updates expected later in 2025.
On May 28, 2025, Precision BioSciences, Inc. held its annual meeting of stockholders, where 71% of the common stock was represented. The meeting resulted in the election of Kevin J. Buehler and Shari Lisa Piré as Class III directors, and the approval of several proposals, including the ratification of Deloitte & Touche LLP as the independent accounting firm and an annual advisory vote on executive compensation. However, a proposal to amend the Certificate of Incorporation regarding officer exculpation did not pass as it failed to meet the required voting threshold.